Nanshan Chen's scientific contributions

Publications (12)

Article
Full-text available
Background Coronavirus disease 2019 (COVID-19) is associated with coagulation abnormalities which are indicators of higher mortality especially in severe cases. Methods We studied patients with proven COVID-19 disease in the intensive care unit of Jinyintan Hospital, Wuhan, China from 30 to 2019 to 31 March 2020. Results Of 180 patients, 89 (49.4...
Article
Full-text available
Setting The shorter treatment regimen (STR) for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) has achieved successful outcomes in many countries. However, there are few studies on high-dose gatifloxacin-based STR with adverse drug reactions (ADRs) and management. Design A prospective observational study was conducted with MDR/RR-TB p...
Article
Full-text available
Background: Since 2020 COVID-19 pandemic became an emergent public sanitary incident. The epidemiology data and the impact on prognosis of secondary infection in severe and critical COVID-19 patients in China remained largely unclear. Methods: We retrospectively reviewed medical records of all adult patients with laboratory-confirmed COVID-19 wh...
Preprint
Full-text available
Background. Since 2020 COVID-19 pandemic became an emergent public sanitary incident. The epidemiology data and the impact on prognosis of secondary infection in severe and critical COVID-19 patients in China remained largely unclear. Methods. We retrospectively reviewed medical records of all adult patients with laboratory-confirmed COVID-19 who w...
Article
Full-text available
Background The clinical correlates, prognosis and determinants of acute kidney injury (AKI) in patients with coronavirus disease 2019 (Covid-19) remain largely unclear. Methods We retrospectively reviewed medical records of all adult patients with laboratory-confirmed Covid-19 who were admitted to the intensive care unit (ICU) between January 23rd...
Article
Full-text available
In patients with critically ill COVID-19 pneumonia, lower airways are filled with plenty of highly viscous exudates or mucus, leading to airway occlusion. The estimation of airway opening pressures and effective mucus clearance are therefore two issues that clinicians are most concerned about during mechanical ventilation. In this study we retrospe...
Preprint
Full-text available
Background: Since the clinical correlates, prognosis and determinants of AKI in patients with Covid-19 remain largely unclear, we perform a retrospective study to evaluate the incidence, risk factors and prognosis of AKI in severe and critically ill patients with Covid-19. Methods: We reviewed medical records of all adult patients (>18 years) with...
Article
Background: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or l...
Article
Background: In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods: In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospit...

Citations

... However, given the predominant role of pulmonary disease in determining severe COVID-19 disease and mortality, the presence of Candida in the lower respiratory tract may be of particular relevance in COVID-19 compared to other conditions requiring hospitalisation and admission to ICU. In line with this approach, other authors have reported information on rates of presence of Candida in the lower respiratory tract of patients with COVID-19 [23][24][25]. ...
... Third, to determine COVID-19 associated thromboembolism, Sequential Organ Failure Assessment (SOFA) score that is one of the disease severity and organ failure scores has been evaluated by some previous studies. 4,5 These studies suggest that in critically ill COVID-19 patients, higher SOFA scores are associated with higher DVT frequency, D-dimer levels, duration of disease, hypoalbuminemia, and duration of disease. 4 Other previous study 5 reported that higher ISTH SIC scores which include SOFA score, prothrombin time-international normalised ratio (PT-INR), and platelet levels are associated with higher mortality and patients with ISTH SIC score higher than 3 had 3.05-fold increased mortality risk. ...
... The kidney is one of the organs most affected by SARS-CoV-2 in severely ill patients. Acute kidney injury (AKI) from SARS-CoV-2 infection is common and sometimes results in the need for kidney replacement therapy (KRT), as required in other causes of AKI 9,10 . ...
... [6] reported a P aCO 2 -P ETCO 2 gap of 15 mmHg in COVID-19 patients who need a high F IO 2 to maintain S aO 2 . In critically ill COVID-19 patients, as presented by CHEN et al. [7], the P aCO 2 -P ETCO 2 gap is reached at very high levels of 33 mmHg (18-40 mmHg). ...
... Mucus production stimulated by IFN-AhR signalling triggers hypoxia in a mouse model of COVID-19 [20]. Lower airway viscous secretions in COVID-19 lead to the requirement for a high inspiratory plateau pressure, which required suction pressure of 20 KPa causing closure of distal airways [21]. Stickiness of sputum in associated with more severe disease in COVID-19 patients [22]. ...
... The COVID-19 disease caused by the coronavirus 2 (SARS-CoV-2) was first identified in 43 December 2019 in Wuhan, China(Lu et al. 2020;Xu et al. 2020). It quickly spread throughout 44 China and other countries in the following months, becoming a global public health concern 45 (Chen et al. 2020a; Chen et al. 2020b;Chen and Li 2020;Gilbert et al. 2020;Li et al. 2020;46 Sohrabi et al. 2020). In general, most people with SARS-CoV-2 have mild symptoms such as 47 fever, dry cough, and sore throat (Huang et al. 2020;Sohrabi et al. 2020). ...
... Most patients received a combination of antiviral treatment, lopinavir/ritonavir and hydroxychloroquine. No decrease in mortality was seen with the administration of lopinavir/ritonavir in a randomized clinical trial of COVID-19 patients [27]; however, the study included only severe patients and these findings cannot be extrapolated to our context [28,29]. Recently, two randomized clinical trials have published their results, the RECOV-ERY trial a randomized open clinical trial who did not find any benefit in 28-days mortality rate in hospitalized COVID-19 patients who received lopinavir/ritonavir [30]; and the MIRACLE trial a double blind randomized clinical trial exploring the combination of lopinavir/ritonavir and interferon Beta-1b in the treatment of Middle East Respiratory Syndrome (MERS) that demonstrated a lower mortality with this combination, especially if started in the first 7 days of symptoms [31]. ...
... Interplay of multiple factors including diabetes mellitus, respiratory illness, immunosuppressive therapy, hospital-acquired infection and systemic immune alterations by Covid-19 infection may cause secondary infections [17,18]. Covid-19 patients have reported an overexpression of inflammatory cytokines. ...